These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37670807)

  • 1. SARS-CoV-2 mRNA Vaccine Elicits Sustained T Cell Responses Against the Omicron Variant in Adolescents.
    Choi S; Kim SH; Han MS; Yoon Y; Kim YK; Cho HK; Yun KW; Song SH; Ahn B; Kim YK; Choi SH; Choe YJ; Lim H; Choi EB; Kim K; Hyeon S; Lim HJ; Kim BC; Lee YK; Choi EH; Shin EC; Lee H
    Immune Netw; 2023 Aug; 23(4):e33. PubMed ID: 37670807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
    Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
    Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNT162b2-induced memory T cells respond to the Omicron variant with preserved polyfunctionality.
    Jung MK; Jeong SD; Noh JY; Kim DU; Jung S; Song JY; Jeong HW; Park SH; Shin EC
    Nat Microbiol; 2022 Jun; 7(6):909-917. PubMed ID: 35577972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impacts of delta and omicron variants on inactivated SARS-CoV-2 vaccine-induced T cell responses in patients with autoimmune diseases and healthy controls.
    Wang S; Li J; Wang S; Ye Y; Li M; Liu Y; Chen B; Lai Y; Li L; Zhuang L; Peng S; Yang N; Zhang H; Xiao H
    Clin Transl Med; 2023 Jan; 13(1):e1171. PubMed ID: 36639826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.
    Goh YS; Rouers A; Fong SW; Zhuo NZ; Hor PX; Loh CY; Huang Y; Neo VK; Kam IKJ; Wang B; Ngoh EZX; Salleh SNM; Lee RTC; Pada S; Sun LJ; Ong DLS; Somani J; Lee ES; ; ; Maurer-Stroh S; Wang CI; Leo YS; Ren EC; Lye DC; Young BE; Ng LFP; Renia L
    Front Immunol; 2022; 13():1031852. PubMed ID: 36451833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose.
    Beaudoin-Bussières G; Tauzin A; Dionne K; Gendron-Lepage G; Medjahed H; Perreault J; Levade I; Alfadhli L; Bo Y; Bazin R; Côté M; Finzi A
    Viruses; 2023 May; 15(6):. PubMed ID: 37376574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
    Soto JA; Melo-González F; Gutierrez-Vera C; Schultz BM; Berríos-Rojas RV; Rivera-Pérez D; Piña-Iturbe A; Hoppe-Elsholz G; Duarte LF; Vázquez Y; Moreno-Tapia D; Ríos M; Palacios PA; Garcia-Betancourt R; Santibañez Á; Pacheco GA; Mendez C; Andrade CA; Silva PH; Diethelm-Varela B; Astudillo P; Calvo M; Cárdenas A; González M; Goldsack M; Gutiérrez V; Potin M; Schilling A; Tapia LI; Twele L; Villena R; Grifoni A; Sette A; Weiskopf D; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Retamal-Díaz A; Muñoz-Jofré N; ; Meng X; Xin Q; Alarcón-Bustamante E; González-Aramundiz JV; Le Corre N; Álvarez-Figueroa MJ; González PA; Abarca K; Perret C; Carreño LJ; Bueno SM; Kalergis AM
    mBio; 2022 Dec; 13(6):e0131122. PubMed ID: 36383021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals.
    Emmelot ME; Vos M; Boer MC; Rots NY; de Wit J; van Els CACM; Kaaijk P
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.
    Peled Y; Afek A; Kreiss Y; Rahav G; Nemet I; Kliker L; Indenbaum V; Ram E; Lavee J; Segev A; Matezki S; Sternik L; Raanani E; Lustig Y; Patel JK; Mandelboim M
    J Heart Lung Transplant; 2022 Oct; 41(10):1417-1425. PubMed ID: 35710484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
    Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
    J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BNT162b2 vaccine induces humoral and cellular immune memory to SARS-CoV-2 Wuhan strain and the Omicron variant in children 5 to 11 years of age.
    Cinicola BL; Piano Mortari E; Zicari AM; Agrati C; Bordoni V; Albano C; Fedele G; Schiavoni I; Leone P; Fiore S; Capponi M; Conti MG; Petrarca L; Stefanelli P; Spalice A; Midulla F; Palamara AT; Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2022; 13():1094727. PubMed ID: 36591287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Model.
    Prakash S; Dhanushkodi NR; Singer M; Quadiri A; Zayou L; Vahed H; Coulon PG; Ibraim IC; Tafoya C; Hitchcock L; Landucci G; Forthal DN; El Babsiri A; Tifrea DF; Figueroa CJ; Nesburn AB; Kuppermann BD; Gil D; Jones TM; Ulmer JB; BenMohamed L
    bioRxiv; 2024 Feb; ():. PubMed ID: 38405942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV.
    Casado JL; Vizcarra P; Martín-Colmenarejo S; Del Pino J; Gomez-Maldonado S; Martín-Hondarza A; Vallejo A
    AIDS; 2023 May; 37(6):877-882. PubMed ID: 36779501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.